Navamedic ASA will present the Q1 results on May 11 at 0830 CET

“We work systematically to strengthen our core business by delivering growth through the introduction of new products in existing markets and expanding products to new geographies. We have started and will continue the tedious process to increase company value by owning new products and brands. As a third step, we have been and will actively continue to source and evaluate M&A opportunities to deliver sustainable growth with the objective of building Navamedic to a leading Nordic pharmaceutical company with a footprint in North Europe and other selected countries,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.